Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1982 1
1983 5
1984 4
1985 5
1986 5
1987 8
1988 13
1989 6
1990 4
1991 5
1992 3
1993 2
1994 3
1995 1
1996 4
1997 2
1998 3
1999 1
2001 1
2002 1
2003 2
2004 2
2005 1
2006 2
2008 3
2010 1
2011 2
2012 1
2013 2
2015 2
2016 2
2018 2
2019 3
2020 3
2021 3
2022 1
2023 2
2024 1
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

113 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Comparison of the efficacy of cefoperazone-sulbactam and other cephalosporins in the treatment of infections: A systematic review and meta-analysis.
Sun W, Zhang J, Miao K, Ju L, Yuan H. Sun W, et al. Medicine (Baltimore). 2025 Apr 25;104(17):e42182. doi: 10.1097/MD.0000000000042182. Medicine (Baltimore). 2025. PMID: 40295277 Free PMC article.
BACKGROUND: Cefoperazone-sulbactam is a broad-spectrum antibiotic known for its activity against a wide range of pathogens, including multidrug-resistant organisms (MDROs). ...Adverse reactions were similar between groups, with cefoperazone-sulbactam demonstrating g …
BACKGROUND: Cefoperazone-sulbactam is a broad-spectrum antibiotic known for its activity against a wide range of pathogens, including …
Efficacy and safety of cefoperazone-sulbactam in empiric therapy for febrile neutropenia: A systemic review and meta-analysis.
Lan SH, Chang SP, Lai CC, Lu LC, Tang HJ. Lan SH, et al. Medicine (Baltimore). 2020 Feb;99(8):e19321. doi: 10.1097/MD.0000000000019321. Medicine (Baltimore). 2020. PMID: 32080150 Free PMC article.
Only clinical trials comparing cefoperazone-sulbactam with other antibiotics for empiric treatment of febrile neutropenia were included. ...CONCLUSION: The clinical efficacy and tolerability of cefoperazone-sulbactam are comparable to those of comparator drugs in th …
Only clinical trials comparing cefoperazone-sulbactam with other antibiotics for empiric treatment of febrile neutropenia were includ …
Clinical Efficacy and Safety of Cefoperazone-Sulbactam in Treatment of Intra-Abdominal Infections: A Systematic Review and Meta-Analysis.
Lan SH, Chao CM, Chang SP, Lu LC, Lai CC. Lan SH, et al. Surg Infect (Larchmt). 2021 Oct;22(8):763-770. doi: 10.1089/sur.2020.468. Epub 2021 Feb 23. Surg Infect (Larchmt). 2021. PMID: 33625294
Overall, the clinical efficacy rate of cefoperazone-sulbactam and comparators was 87.7% and 81.7%, respectively, and cefoperazone-sulbactam was associated with a higher clinical efficacy rate than that the comparator (odds ratio [OR] 1.98; 95% confidence interval [C …
Overall, the clinical efficacy rate of cefoperazone-sulbactam and comparators was 87.7% and 81.7%, respectively, and cefoperazone …
Efficacy and safety of generic cefoperazone/sulbactam versus branded cefoperazone/sulbactam in the treatment of bacterial infections: a systematic review and meta-analysis.
Wu R, Wang X, Cui P, Chen W, Yang W, Lai Y. Wu R, et al. J Chemother. 2024 Dec;36(8):698-708. doi: 10.1080/1120009X.2024.2343961. Epub 2024 Apr 21. J Chemother. 2024. PMID: 38644652
This study aim to assess the clinical efficacy and safety of generic cefoperazone/sulbactam compared to the branded cefoperazone/sulbactam (Sulperazon) in treating bacterial infections through a meta-analysis. ...Meta-analysis of the RCTs indicated no statistical di …
This study aim to assess the clinical efficacy and safety of generic cefoperazone/sulbactam compared to the branded cefoperazone …
Cefoperazone versus combination antibiotic therapy of hospital-acquired pneumonia.
Mangi RJ, Greco T, Ryan J, Thornton G, Andriole VT. Mangi RJ, et al. Am J Med. 1988 Jan;84(1):68-74. doi: 10.1016/0002-9343(88)90010-1. Am J Med. 1988. PMID: 3276187 Clinical Trial.
Cefoperazone was as effective as either clindamycin/gentamicin or cefazolin/gentamicin (cure rate: 45 of 52 cefoperazone-treated patients [87 percent], versus 44 of 61 combination-therapy patients [72 percent], p = 0.069). ...When antibiotic costs, administration co …
Cefoperazone was as effective as either clindamycin/gentamicin or cefazolin/gentamicin (cure rate: 45 of 52 cefoperazone-treat …
Cefoperazone versus ceftazidime monotherapy of nosocomial pneumonia.
Mangi RJ, Ryan J, Berenson C, Greco T, Simms M 3rd, Thornton G, Andriole VT. Mangi RJ, et al. Am J Med. 1988 Jul 25;85(1A):44-8. doi: 10.1016/0002-9343(88)90174-x. Am J Med. 1988. PMID: 3041818 Clinical Trial.
Cefoperazone and ceftazidime monotherapy were compared in a randomized, prospective evaluation of patients with nosocomial pneumonia. ...When antibiotic administration, and laboratory costs are considered, cefoperazone is less expensive than ceftazidime. Both cef …
Cefoperazone and ceftazidime monotherapy were compared in a randomized, prospective evaluation of patients with nosocomial pneumonia. …
Randomized Noninferiority Trial of Cefoperazone-Sulbactam versus Cefepime in the Treatment of Hospital-Acquired and Healthcare-Associated Pneumonia.
Liu JW, Chen YH, Lee WS, Lin JC, Huang CT, Lin HH, Liu YC, Chuang YC, Tang HJ, Chen YS, Ko WC, Lu MC, Wang FD. Liu JW, et al. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00023-19. doi: 10.1128/AAC.00023-19. Print 2019 Aug. Antimicrob Agents Chemother. 2019. PMID: 31138577 Free PMC article. Clinical Trial.
To clarify the clinical effects of cefoperazone-sulbactam in the treatment of HAP and HCAP, we conducted an open-label, randomized, noninferiority trial that recruited patients aged 18 years suffering HAP/HCAP. ...Serious adverse events were rare, and none was judged to b …
To clarify the clinical effects of cefoperazone-sulbactam in the treatment of HAP and HCAP, we conducted an open-label, randomized, n …
Cefoperazone-sulbactam for treatment of intra-abdominal infections: results from a randomized, parallel group study in India.
Chandra A, Dhar P, Dharap S, Goel A, Gupta R, Hardikar JV, Kapoor VK, Mathur AK, Modi P, Narwaria M, Ramesh MK, Ramesh H, Sastry RA, Shah S, Virk S, Sudheer OV, Sreevathsa MR, Varshney S, Kochhar P, Somasundaram S, Desai C, Schou M. Chandra A, et al. Surg Infect (Larchmt). 2008 Jun;9(3):367-76. doi: 10.1089/sur.2007.013. Surg Infect (Larchmt). 2008. PMID: 18570578 Clinical Trial.
On microbiologic outcomes, cefoperazone-sulbactam had higher success rates than ceftazidime-amikacin-metronidazole (92.9% vs. 80.0%). ...CONCLUSION: Empirical cefoperazone-sulbactam monotherapy could be a useful adjunct to surgical intervention for intra-abdominal i …
On microbiologic outcomes, cefoperazone-sulbactam had higher success rates than ceftazidime-amikacin-metronidazole (92.9% vs. 80.0%). …
Effectiveness of Cefoperazone-sulbactam alone and Combined with Tigecycline in the Treatment of Multi-drug Resistant Acinetobacter Baumannii Pulmonary Infection.
Lv Q, Deng Y, Zhu X, Ruan J, Chen L. Lv Q, et al. J Coll Physicians Surg Pak. 2020 Mar;30(3):332-334. doi: 10.29271/jcpsp.2020.03.332. J Coll Physicians Surg Pak. 2020. PMID: 32169149 Clinical Trial.
The aim of this study was to compare the effectiveness of cefoperazone-sulbactam alone and combined with tigecycline in the treatment of multi-drug resistant acinetobacter baumannii pulmonary infection. ...One hundred and fourteen patients with multi-drug resistant acineto …
The aim of this study was to compare the effectiveness of cefoperazone-sulbactam alone and combined with tigecycline in the treatment …
Cefoperazone versus ceftriaxone monotherapy of nosocomial pneumonia.
Mangi RJ, Peccerillo KM, Ryan J, Berenson C, Greco T, Thornton G, Andriole VT. Mangi RJ, et al. Diagn Microbiol Infect Dis. 1992 Jul;15(5):441-7. doi: 10.1016/0732-8893(92)90086-9. Diagn Microbiol Infect Dis. 1992. PMID: 1643821 Clinical Trial.
The development of secondary pneumonia with resistant bacteria was low, 3% with cefoperazone and 4% with ceftriaxone. When antibiotic, administrative, and laboratory costs were calculated, cefoperazone was slightly less expensive than ceftriaxone. Both cefoperazo …
The development of secondary pneumonia with resistant bacteria was low, 3% with cefoperazone and 4% with ceftriaxone. When antibiotic …
113 results